Find a Research Study

Find a Research Study

Find a Research Study

Find a Research Study

Find a Research Study

A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer

This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and t


Why this Research Matters

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progres


Who can Participate

Adult

Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov: https://clinicalt


Study ID

Protocol Number: 24-1686

More information available at ClinicalTrials.gov: NCT06369285


Meet the Team

Image of Principal Investigator

Jennifer Diamond, MD

Principal Investigator